CA3107270A1 - Method for producing tetracyclic compound - Google Patents
Method for producing tetracyclic compound Download PDFInfo
- Publication number
- CA3107270A1 CA3107270A1 CA3107270A CA3107270A CA3107270A1 CA 3107270 A1 CA3107270 A1 CA 3107270A1 CA 3107270 A CA3107270 A CA 3107270A CA 3107270 A CA3107270 A CA 3107270A CA 3107270 A1 CA3107270 A1 CA 3107270A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- formula
- compound represented
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018165313 | 2018-09-04 | ||
| JP2018-165313 | 2018-09-04 | ||
| PCT/JP2019/034543 WO2020050241A1 (ja) | 2018-09-04 | 2019-09-03 | ４環性化合物の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107270A1 true CA3107270A1 (en) | 2020-03-12 |
Family
ID=69722303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107270A Pending CA3107270A1 (en) | 2018-09-04 | 2019-09-03 | Method for producing tetracyclic compound |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11939322B2 (https=) |
| EP (1) | EP3848361B1 (https=) |
| JP (1) | JP7167171B2 (https=) |
| KR (1) | KR102635225B1 (https=) |
| CN (1) | CN112585126B (https=) |
| AR (1) | AR116113A1 (https=) |
| AU (1) | AU2019337018B2 (https=) |
| BR (1) | BR112021001145A2 (https=) |
| CA (1) | CA3107270A1 (https=) |
| ES (1) | ES3010145T3 (https=) |
| HR (1) | HRP20250284T1 (https=) |
| HU (1) | HUE070227T2 (https=) |
| IL (1) | IL281079B2 (https=) |
| MX (1) | MX2021002311A (https=) |
| PL (1) | PL3848361T3 (https=) |
| SG (1) | SG11202100983XA (https=) |
| TW (1) | TWI825163B (https=) |
| WO (1) | WO2020050241A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4285907A4 (en) | 2021-01-29 | 2024-11-13 | Chugai Seiyaku Kabushiki Kaisha | Drug composition for treating pediatric cancers |
| CN117024410A (zh) * | 2023-08-15 | 2023-11-10 | 上海药坦药物研究开发有限公司 | 一种艾乐替尼中间体及其制备方法 |
| WO2025067412A1 (zh) * | 2023-09-28 | 2025-04-03 | 重庆博腾制药科技股份有限公司 | 一种抗肿瘤药物中间体的制备方法 |
| CN120081779A (zh) * | 2025-02-19 | 2025-06-03 | 江苏天士力帝益药业有限公司 | 一种阿来替尼杂质01a及其控制方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS506987B1 (https=) | 1970-02-17 | 1975-03-19 | ||
| JPS4918630B1 (https=) | 1970-07-29 | 1974-05-11 | ||
| JPS5859712U (ja) | 1981-10-16 | 1983-04-22 | ニチバン株式会社 | ラベル貼付機 |
| JPH0892090A (ja) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| EP0695755B1 (en) | 1994-08-04 | 1998-10-21 | F. Hoffmann-La Roche AG | Pyrrolocarbazole |
| EA001450B1 (ru) | 1996-05-01 | 2001-04-23 | Эли Лилли Энд Компани | Галогензамещенные ингибиторы протеинкиназы с |
| ES2292262T3 (es) * | 1998-12-24 | 2008-03-01 | Astellas Pharma Inc. | Compuestos de imidazol y su uso medicinal. |
| EP1178988B1 (en) | 1999-05-14 | 2007-02-28 | The Australian National University | Compounds and therapeutic methods |
| GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
| FR2841138B1 (fr) | 2002-06-25 | 2005-02-25 | Cll Pharma | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
| EP1603567A4 (en) | 2003-02-28 | 2006-10-18 | Inotek Pharmaceuticals Corp | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF |
| ES2263862T3 (es) | 2003-03-07 | 2006-12-16 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| PT1687305E (pt) | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| JP2007513890A (ja) | 2003-12-12 | 2007-05-31 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害剤 |
| TW200609215A (en) | 2004-03-19 | 2006-03-16 | Speedel Experimenta Ag | Organic compounds |
| WO2005092062A2 (en) * | 2004-03-19 | 2005-10-06 | Myriad Genetics, Inc. | Compounds for neurodegenerative disorders |
| JP2008502595A (ja) | 2004-03-31 | 2008-01-31 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼモジュレータおよびその使用方法 |
| MXPA06014066A (es) * | 2004-06-02 | 2007-02-15 | Pharmacyclics Inc | Inhibicion de factor viia. |
| DE602005020465D1 (de) | 2004-08-26 | 2010-05-20 | Pfizer | Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer |
| US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| RU2008122547A (ru) | 2005-11-07 | 2009-12-20 | Айрм Ллк (Bm) | Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом) |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| EP2142551B1 (en) | 2007-04-17 | 2015-10-14 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| PT2176231T (pt) | 2007-07-20 | 2016-12-09 | Nerviano Medical Sciences Srl | Derivados de indazol substituídos activos como inibidores de quinases |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| US20110038898A1 (en) | 2008-03-13 | 2011-02-17 | Shuichi Yada | Dissolution properties of drug products containing olmesartan medoxomil |
| MX2011011661A (es) | 2009-05-07 | 2011-11-18 | Astrazeneca Ab | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| ES2575084T3 (es) | 2009-06-10 | 2016-06-24 | Chugai Seiyaku Kabushiki Kaisha | Compuesto tetracíclico |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| CN103052386B (zh) | 2010-08-20 | 2016-03-02 | 中外制药株式会社 | 含有四环化合物的组合物 |
| JP5006987B2 (ja) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| MY170904A (en) | 2012-09-25 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| JP6873698B2 (ja) | 2014-04-25 | 2021-05-19 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| TWI831128B (zh) | 2014-04-25 | 2024-02-01 | 日商中外製藥股份有限公司 | 以高用量含有４環性化合物的製劑 |
| WO2015193309A1 (en) | 2014-06-18 | 2015-12-23 | F. Hoffmann-La Roche Ag | New pharmaceutical composition comprising non-ionic surfactants |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| CN104402862B (zh) * | 2014-11-12 | 2016-10-05 | 苏州明锐医药科技有限公司 | 艾立替尼的制备方法 |
| US9573932B2 (en) | 2015-03-02 | 2017-02-21 | Yong Xu | Synthesis of intermediates in the preparation of ALK inhibitor |
| WO2017073706A1 (ja) * | 2015-10-30 | 2017-05-04 | 中外製薬株式会社 | ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体 |
| CN106928184B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
| CN106928185B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
| CN107033124B (zh) * | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | 一种艾乐替尼的制备方法 |
-
2019
- 2019-09-03 PL PL19856540.0T patent/PL3848361T3/pl unknown
- 2019-09-03 CA CA3107270A patent/CA3107270A1/en active Pending
- 2019-09-03 WO PCT/JP2019/034543 patent/WO2020050241A1/ja not_active Ceased
- 2019-09-03 CN CN201980056366.1A patent/CN112585126B/zh active Active
- 2019-09-03 JP JP2020541220A patent/JP7167171B2/ja active Active
- 2019-09-03 MX MX2021002311A patent/MX2021002311A/es unknown
- 2019-09-03 TW TW108131697A patent/TWI825163B/zh active
- 2019-09-03 US US17/271,437 patent/US11939322B2/en active Active
- 2019-09-03 EP EP19856540.0A patent/EP3848361B1/en active Active
- 2019-09-03 HR HRP20250284TT patent/HRP20250284T1/hr unknown
- 2019-09-03 SG SG11202100983XA patent/SG11202100983XA/en unknown
- 2019-09-03 ES ES19856540T patent/ES3010145T3/es active Active
- 2019-09-03 KR KR1020217005965A patent/KR102635225B1/ko active Active
- 2019-09-03 AR ARP190102518A patent/AR116113A1/es unknown
- 2019-09-03 IL IL281079A patent/IL281079B2/en unknown
- 2019-09-03 AU AU2019337018A patent/AU2019337018B2/en active Active
- 2019-09-03 HU HUE19856540A patent/HUE070227T2/hu unknown
- 2019-09-03 BR BR112021001145-5A patent/BR112021001145A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019337018B2 (en) | 2024-03-07 |
| IL281079B1 (en) | 2024-08-01 |
| HUE070227T2 (hu) | 2025-05-28 |
| US20220372025A1 (en) | 2022-11-24 |
| WO2020050241A1 (ja) | 2020-03-12 |
| CN112585126B (zh) | 2024-05-07 |
| HRP20250284T1 (hr) | 2025-04-25 |
| AR116113A1 (es) | 2021-03-31 |
| EP3848361A1 (en) | 2021-07-14 |
| EP3848361C0 (en) | 2025-01-22 |
| EP3848361A4 (en) | 2022-06-15 |
| EP3848361B1 (en) | 2025-01-22 |
| TW202024050A (zh) | 2020-07-01 |
| KR20210053890A (ko) | 2021-05-12 |
| CN112585126A (zh) | 2021-03-30 |
| JPWO2020050241A1 (ja) | 2021-08-30 |
| JP7167171B2 (ja) | 2022-11-08 |
| IL281079B2 (en) | 2024-12-01 |
| PL3848361T3 (pl) | 2025-07-07 |
| AU2019337018A1 (en) | 2021-03-18 |
| SG11202100983XA (en) | 2021-03-30 |
| ES3010145T3 (en) | 2025-04-01 |
| MX2021002311A (es) | 2021-04-28 |
| BR112021001145A2 (pt) | 2021-04-20 |
| IL281079A (en) | 2021-04-29 |
| TWI825163B (zh) | 2023-12-11 |
| US11939322B2 (en) | 2024-03-26 |
| KR102635225B1 (ko) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6392436B2 (ja) | 置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法 | |
| EP3848361B1 (en) | Method of producing tetracyclic compound | |
| RU2752384C2 (ru) | Способ получения триазолопиридинового соединения | |
| AU2016276573A1 (en) | Methods of making protein deacetylase inhibitors | |
| EP3668857A1 (en) | Processes for the preparation of niraparib and intermediates thereof | |
| CA2992622A1 (en) | Cgrp receptor antagonists | |
| JP2020518573A (ja) | ２−（［１，２，３］トリアゾール−２−イル）−安息香酸誘導体の製造 | |
| CN104837817B (zh) | 制备3‑氨基‑哌啶化合物的合成路线 | |
| WO2015018289A1 (zh) | 一种合成阿哌沙班重要中间体的新方法 | |
| BRPI0708560A2 (pt) | processo para a preparação de um composto, e, composto | |
| TWI884151B (zh) | 製備4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氫嘧啶-6-基]甲基]-3-側氧-5,6,8,8a-四氫-1H-咪唑并[1,5-a]吡-2-基]-羧酸之替代方法 | |
| HK40051429B (zh) | 四环化合物的制备方法 | |
| HK40051429A (en) | Method of producing tetracyclic compound | |
| TW202610622A (zh) | 2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1s,3r)-3-(羥甲基)-5-(1-羥基-1-甲基-乙基)-1-甲基-3,4-二氫-1h-異喹啉-2-基]乙酮一水合物之製造方法 | |
| JPWO2010029756A1 (ja) | ５−［２−（メチルチオ）エトキシ］ピリミジン−２−アミンの製造方法 | |
| JP2018070607A (ja) | アミノ基で置換されたオキサジアゾール誘導体の製造方法 | |
| NZ724215B2 (en) | Method for producing substituted 5-fluoro-1h-pyrazolopyridines | |
| JP2008273840A (ja) | ベンジルアミン誘導体の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230531 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240823 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240823 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240823 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241017 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20241031 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250123 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250627 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D133 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (IN EXAMINATION) DETERMINED COMPLIANT Effective date: 20250627 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250627 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250627 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250627 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250627 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250815 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250815 |